Introduction
Hair grows from a single follicle - an indentation in the skin. Each hair follicle has its own blood, nerve and muscle supply. Every individual is born with a specific number of follicles, which cannot be changed, and the size of one’s hair follicle determines the thickness of one’s hairs.

At the base of each follicle, lying on the dermis (the deeper layer of the skin), is the papilla – the bud of hair where most growth takes place. The blood vessels that surround follicles carry the nourishment one’s hair needs to grow. This is one of the reasons why diet is so important for healthy hair growth and strength.

When blood vessels in the scalp are cooled, they become narrower, and so less blood flows through them. Cooling the scalp during chemotherapy means that less of the chemotherapy drug reaches the hair follicles. This means the hair is less likely to fall out.

Loosing Hair Following Chemotherapy
Chemotherapy drugs are powerful medications that attack rapidly growing cancer cells. Unfortunately, these drugs also attack other rapidly growing cells in the body - including those in the hair roots.

Chemotherapy may cause hair loss all over the body - not just on the scalp. Sometimes even the eyelashes, eyebrows,
armpits, pubic and other body hair also fall out. Some chemotherapy drugs are more likely than others to cause hair loss, and different doses of chemotherapy drugs can cause anything from a mere thinning of hair to complete baldness.

Fortunately, most of the time hair loss from chemotherapy is temporary. One can expect one’s hair to regrow three to ten months after chemotherapy treatment ends, though the hair may temporarily be a different shade or texture.

The loss of hair that comes as a side effect of many chemotherapy agents can be a devastating part of cancer treatment. Some patients see it as not just a blow to their vanity, but as a constant, visual reminder of their illness.

Hair loss is one of the most well-known side effects of cancer treatment. Some cancer drugs may cause:

- Mild thinning of hair
- Partial hair loss, or loss of patches of hair
- Complete hair loss (alopecia)

Generally, chemotherapy is the type of cancer treatment most likely to cause hair loss. Complete hair loss is very unlikely with any other type of cancer treatment. But some other cancer drugs can cause hair thinning. One cannot tell beforehand who will be affected or how badly someone may be affected by chemotherapy drugs. Some drugs are more likely to cause hair loss than others.

Hair loss also depends on other factors such as:
- The type of drug or combination of drugs the patient is taking
- The dose of the drug(s) that are given
- One’s individual sensitivity to the drug(s)
- One’s drug treatment in the past

**Chemotherapy Drugs that Usually Cause Hair Loss**

Of the chemotherapy drugs commonly used to treat cancer, several are known to cause hair loss. It is important to keep in mind, however, that many factors such as the dose, route of administration, combination of drugs, and other individual characteristics will all impact on whether or not hair loss occurs as well as the degree of hair loss experienced.

The chemotherapy drugs most often associated with hair loss are:

- **Adriamycin (doxorubicin)** - often causes hair loss. When administered as an injection every three to four weeks, hair loss is usually total including eyebrows, eyelashes and pubic hair. Weekly injections of lower doses are associated with minimal or no hair loss
- **Carboplatin** - when used alone rarely causes hair loss. When used in combination with Cytoxan (cyclophosphamide), hair loss occurs about half of the time
- **Cisplatin** - may cause hair loss; however, this side effect is uncommon
- **Cytoxan (cyclophosphamide)** - commonly causes hair loss
- **Dactinomycin** - may cause hair loss which is not limited to the scalp
- **Etoposide** - may cause mild hair loss in some patients, although some patients develop total baldness
Hexamethamelamine (HMM, altretamine) - may cause hair loss; however, this side effect is uncommon

Ifosfamide - commonly causes hair loss

Taxol - causes hair loss in almost 100% of patients. Hair loss usually occurs 14 to 21 days after treatment and often affects all body hair including eyebrows, eyelashes, and pubic hair

Vincristine - causes hair loss in less than half of patients.

Other chemotherapy drugs which are less frequently associated with hair loss, either because the frequency of hair loss or degree of hair loss is less, include: bleomycin, 5-fluorouracil (5-FU), and methotrexate.

Coping with hair loss
If worried about hair loss or thinning of hair from cancer treatment, the tips below might help. Ask the treating physician or nurse if the cancer drugs prescribed for you will cause hair loss.

If complete hair loss is a possibility:
- Ask about a wig before treatment commences, in order to match the colour and texture with one’s real hair
- If feeling adventurous, choose a wig for a whole new look – why not the colour and style you have always wanted!
- Think about having hair cut short before treatment starts
- Some people shave their hair off completely to avoid the distress of seeing the hair fall out
- Wear a hair net at night not to wake up with hair all over the pillow, as this can be upsetting

For hair loss or thinning:
- Use gentle hair products such as baby shampoos
- Do not use perms or hair colours on thinning hair - colours may not take well and perms can damage the hair
- Use a soft baby brush and comb the thinning hair gently
- Try not to brush or comb thinning hair too hard – a soft baby brush may help
- Avoid using hair dryers, curling tongs and curlers on thinning hair
- Pat the hair dry
- If the scalp flakes or itches this means it is dry – use oil or moisturiser, not dandruff shampoo

The Cool Cap
A cool cap (also known as a ‘hypothermia cap’, ‘cold cap’ or ‘cooling cap’) is a therapeutic device used to cool the human scalp. The most prominent medical applications of this device are said to be in preventing or reducing alopecia (hair loss) as a result of chemotherapy.

![Picture Credit: Baby with Cool Cap]
Worn tight on the head, hypothermia caps are typically made of a synthetic such as neoprene, silicone or polyurethane, and filled with a coolant agent such as ice or gel which is either frozen to a very cold temperature (usually -25°C to -30°C) before application or continuously cooled by an auxiliary attached control unit.

[Picture Credit: The Cool Cap]

It is said that a cool cap can prevent hair loss in up to 80% of patients and that it is particularly effective against the drugs used in treating breast cancer.

**Concerns Over the Use of Scalp Cooling**

Some doctors worry about using scalp cooling with treatment that aims to cure the cancer. There are concerns that cancer cells that may have spread to the scalp may be more likely to survive chemotherapy if scalp cooling is used. However, cancer spreading to the scalp is very uncommon.

Clinical trials have shown that the risk of this occurring as a result of scalp cooling is very small, except in haematological cancers. Some people may prefer not to have scalp cooling because of this, but others are happy to try it. If interested in scalp cooling, talk about it with one’s treating physician.

Scalp cooling is not effective with all chemotherapy drugs. It is most likely to be effective with:

- Cyclophosphamide
- Daunorubicin
- Docetaxel (Taxotere ®)
- Doxorubicin
- Paclitaxel (Taxol (paclitaxel ®).

**Good Candidates for Scalp Cooling**

Scalp cooling is not suitable for everyone. It is not suitable if the following applies:

- Patients who have a haematological cancer such as myeloma, leukaemia or lymphoma. This is because there is a high risk of cancer cells surviving in the blood vessels of the scalp, causing the cancer to come back after treatment
- Patients who need very high doses of chemotherapy, as this makes scalp cooling less likely to work
- Patients having continuous chemotherapy through a pump for several days, as this makes it impractical to have scalp cooling
- Patients whose liver are not working as well as it should be. This may lead to the chemotherapy drugs circulating in the body for longer than usual, and it may not be possible to keep the scalp cold for long enough
- Patients who have severe migraines
• Patients who have already had a first course of chemotherapy and did not have scalp cooling for it

How to Use a Cool Cap
Before embarking or making use of a cool cap, this should be discussed with one’s treating physician.

If approved by the treating physician the cap is worn during each chemotherapy session for:
• 20 to 50 minutes before
• during
• after each chemotherapy session (the amount of time the cap is to be worn after the chemotherapy session depends on the type of chemotherapy the patient receives)

If the patient uses a cool cap that needs to be filled with ice or where the cooled gel needs to be replaced may have to change the cap several times during the chemotherapy treatment. Each cap is usually worn for about 30 minutes; then it warms up and is replaced with a new cap. In the case of caps that are chilled by an external control unit, the cap does not have to be changed during treatment.

Because the caps are so cold, some patients get a headache while wearing the cap. Most patients also get very cold, so it makes sense to dress warmly and bring warm blankets with if it is decided to try the cold cap regime.

Recent Trials in the Use of Scalp Cooling
One of the trials used the Orbis Paxman Hair Loss Prevention System (Paxman Coolers Ltd), is approved by the FDA as well as by the EU. The Paxman device is a two-cap system consisting of an inner silicon cap in which refrigerated fluid is circulated and an outer neoprene cap that insulates the scalp. The cap is fitted snugly to the head and is held in place with a chin strap

[Treatment was deemed to be a success if clinicians blinded to randomization judged patients to have experienced no hair loss or only grade 1 hair loss (<50% hair loss not requiring a wig), as defined by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv4.0) alopecia scale.

At the time of the planned interim analysis, 95 women had been treated with the scalp cooling device and 47 others had received no specific treatment for alopecia.

Results showed that after the fourth cycle of chemotherapy, 50.5% of the cooling group retained their hair, achieving a grade 0 or 1 on the CTCAEv4.0 scale — meaning no wig or scarf was needed — vs 0% of controls.

Researched and Authored by Prof Michael C Herbst
[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; dip Genetic Counselling; Diagnostic Radiographer; Dip Audiology and Noise Measurement; Medical Ethicist]
Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]
October 2019
The second published study used a different scalp cooling device, the DigniCap, developed by Dignitana AB. This device was approved for use in the United States in 2015, and initial results from this study were reported at the time by Medscape Medical News.

In this study, 106 women with early-stage breast cancer used the DigniCap device, and another 16 women served as controls.

Importantly, almost all women in this study received some form of taxane-based chemotherapy, and no women in the scalp cooling group received an anthracycline-based regimen. The mean duration of chemotherapy in this particular study was 2.3 months.

Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward.

Of 101 evaluable patients assigned to the scalp cooling group, 66.3% experienced hair loss of 50% or less from baseline, meaning they had a score of 0 to 2 at study endpoint. This compared to 0% of women in the control group.


Chemotherapy-induced hair loss can be an emotionally distressing adverse effect for patients with breast cancer. However, scalp cooling with the DigniCap system was proven to effectively mitigate hair loss, according to the results of a single-center prospective trial presented at ESMO Congress 2019 in Barcelona, Spain.

The study included 158 women (median age, 49 years) with early stage breast cancer who received anthracycline and/or taxane-based treatment at the Brindisi Oncology Department from February 2016 through January 2019. The success of scalp cooling and hair preservation was determined according to the Dean’s scale. A total of 37 (23.4%) patients who used the scalp cooling system experienced full hair preservation with zero hair loss. Forty-seven (29.7%) patients experienced hair loss of less than 25%, and 31 patients (19.6%) experienced 25% to 50% hair loss. Associated adverse effects included a sense of coldness (81.6%), neck pain (52.2%), and headache (71.5%). A total of 23 patients discontinued use of scalp cooling: 12 (8.4%) due to cold discomfort and 11 (7%) due to unsatisfactory hair preservation.

Interestingly, in patients with 50% or more hair loss, continued use of scalp cooling was associated with observed hair growth. “Our results confirmed and reinforced previous evidences, showing that the DigniCap system has a good chance to prevent [hair loss] during chemotherapy with anthracyline and/or taxane-based regimen and supported the wider use to all women with early stage breast cancer,” the researchers concluded.
Medical Disclaimer
This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this Fact Sheet. So far as permissible by law, the Cancer Association of South Africa (CANSA) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this Fact Sheet.

Whilst CANSA has taken every precaution in compiling this Fact Sheet, neither it, nor any contributor(s) to this Fact Sheet can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this Fact Sheet.

Sources and References Consulted or Utilised

Adelaide Cancer Centre

Baby with Cool Cap
http://www.abclawcenters.com/frequently-asked-questions/what-is-hie

Breast Cancer.Org
http://www.breastcancer.org/tips/hair_skin_nails/cold-caps

Cancer Research UK

Hair Follicle
http://www.passahairdrugtest.com/hair_follicle_drug_test_information.php

Hair Loss
http://www.medicaldaily.com/cold-caps-could-prevent-hair-loss-chemo-patients-how-safe-41-degree-head-cover-247888


MacMillan Cancer Support

Mayo Clinic
http://www.mayoclinic.org/tests-procedures/chemotherapy/in-depth/hair-loss/art-20046920

Medscape

NHS Choices UK
http://www.nhs.uk/Conditions/Chemotherapy/Pages/Side-effects.aspx

Oncolink
http://www.oncolink.org/experts/article.cfm?id=1057

Phillip Kingsley
http://www.philipkingsley.com/hair-guide/hair-science/hair-follicles/


SFGate

The Cool Cap

Wikipedia
http://en.wikipedia.org/wiki/Hypothermia_cap